Skip to main content
. 2021 Oct 23;65(1):65–78. doi: 10.1007/s00125-021-05543-y

Table 3.

Characteristics of participants enrolled in WellGen and ANDIS study by clusters for all participants, and for male and female participants

Characteristic WellGen ANDIS WellGen vs ANDIS
SIDD SIRD MOD MARD p value p1 value SIDD SIRD MOD MARD p value p1 value p value for SIDD p value for MOD
All participants (N = 1612 for WellGen, N = 962 for ANDIS)
 Participants in subroup, n (%) 851 (52.79) 18 (1.12) 608 (37.72) 135 (8.37) 251 (26.09) 35 (3.64) 650 (67.57) 26 (2.7)
 Age at diagnosis, years 36.86 (5.81) 38.83 (4.93) 36.25 (5.77) 40.84 (3.98) 0.005a <0.0001a 38.98 (6.24) 39.94 (5.87) 38.56 (5.9) 42.5 (2.79) <0.0001a <0.0001a <0.0001a <0.0001a
 Duration of diabetes, years 10.49 (8.25) 6.41 (7.16) 8.72 (8.03) 9.83 (8.44) 0.001a -- -- -- -- -- -- -- -- --
 BMI, kg/m2 25.02 (3.45) 28.37 (5.27) 28.4 (4.03) 23.22 (2.44) <0.0001a <0.0001a 28.29 (5.43) 36.62 (6.28) 34.92 (6.41) 24.11 (2.33) <0.0001a <0.0001a <0.0001a <0.0001a
 Fasting glucose, mmol/l 10.77 (3.39) 6.86 (1.89) 7.85 (2.37) 6.50 (1.47) <0.0001a <0.0001a 11.75 (3.67) 7.05 (2.22) 7.97 (2.25) 6.75 (1.26) <0.0001a <0.0001a <0.0001a 0.06
 HbA1c, mmol/mol 87.01 (19.34) 56.7 (13.1) 58.33 (12.92) 47.25 (10.37) <0.0001a <0.0001a 100.6 (19.62) 55.19 (13.79) 58.87 (17.64) 45.85 (7.41) <0.0001a <0.0001a <0.0001a 0.53
 HbA1c, % 10.1 (3.9) 7.3 (3.3) 7.5 (3.3) 6.5 (3.1) <0.0001a <0.0001a 11.4 (4.0) 7.2 (3.4) 7.5 (3.8) 6.3 (2.8) <0.0001a <0.0001a <0.0001a 0.53
 Fasting C-peptide, nmol/l 0.68 (0.39) 1.01 (0.62) 0.89 (0.48) 0.58 (0.29) <0.0001a <0.0001a 0.85 (0.4) 2.53 (0.61) 1.29 (0.48) 0.73 (0.24) <0.0001a <0.0001a <0.0001a <0.0001a
 HOMA2-B 37.66 (22.24) 214.99 (41.01) 77.49 (42.02) 73.74 (31.16) <0.0001a <0.0001a 41.03 (28.34) 968.71 (56.43) 94.79 (38.53) 80.15 (27.62) <0.0001a <0.0001a 0.048 <0.0001a
 HOMA2-IR 2.08 (1.41) 4.73 (1.56) 2.28 (1.29) 1.42 (0.76) 0.314 <0.0001a 2.67 (1.42) 6.17 (1.86) 3.31 (1.42) 1.78 (0.63) <0.0001a <0.0001a 0.043 <0.0001a
Male participants (n = 902 for WellGen, n = 567 for ANDIS)
 Participants in subgroup, n (%) 547 (60.6) 5 (0.55) 230 (25.50) 120 (13.30) 185 (32.6) 16 (2.82) 345 (60.85) 21 (3.7)
 Age at diagnosis, years 36.96 (5.67) 42.07 (10.27) 36.59 (5.43) 40.7 (4.12) <0.0001a <0.0001a 38.91 (6.08) 40.56 (6.19) 39.0 (5.73) 42.05 (2.87) 0.08 0.089 <0.0001a <0.0001a
 Duration of diabetes, years 10.55 (8.70) 8.03 (6.59) 7.71 (7.98) 9.98 (8.56) 0.005a --
 BMI, kg/m2 24.44 (3.08) 28.75 (3.54) 28.77 (3.67) 23.41 (2.34) <0.0001a <0.0001a 27.45 (3.9) 36.74 (6.01) 35.44 (5.9) 24.72 (2.11) <0.0001a <0.0001a <0.0001a <0.0001a
 Fasting glucose, mmol/l 10.29 (3.22) 5.75 (1.0) 7.63 (2.43) 6.52 (1.53) <0.0001a <0.0001a 11.80 (3.5) 7.58 (3.04) 8.16 (2.53) 6.77 (2.53) <0.0001a <0.0001a <0.0001a 0.013
 HbA1c, mmol/mol 84.67 (20.57) 49.07 (10.27) 59.94 (13.35) 47.55 (10.02) <0.0001a <0.0001a 99.58 (20.31) 57.33 (13.82) 64.59 (18.46) 45.30 (7.11) <0.0001a <0.0001a <0.0001a 0.001a
 HbA1c, % 9.9 (4.0) 6.6 (3.1) 7.6 (3.3) 6.5 (3.1) <0.0001a <0.0001a 11.3 (4.0) 7.4 (3.4) 8.1 (3.8) 6.3 (2.8) <0.0001a <0.0001a <0.0001a 0.001a
 Fasting C-peptide, nmol/l 0.66 (0.38) 2.17 (0.44) 1.08 (0.51) 0.60 (0.30) <0.0001a <0.0001a 0.82 (0.35) 2.65 (0.61) 1.36 (0.49) 0.72 (0.49) <0.0001a <0.0001a <0.0001a <0.0001a
 HOMA2-B 39.33 (22.5) 229.16 (40.98) 92.27 (42.49) 75.58 (31.92) <0.0001a <0.0001a 39.15 (25.31) 200.56 (74.37) 98.19 (40.98) 78.57 (27.41) <0.0001a <0.0001a 0.92 0.094
 HOMA2-IR 1.96 (1.34) 4.99 (1.23) 2.76 (1.41) 1.47 (0.78) 0.092 <0.0001a 2.59 (1.27) 6.67 (2.23) 3.56 (1.48) 1.77 (0.65) <0.0001a <0.0001a <0.0001a <0.0001a
Female participants (n = 710 for WellGen, n = 395 for ANDIS)
 Participants in subgroup, n (%) 304 (42.82) 13 (1.83) 378 (53.24) 15 (2.11) 66 (16.7) 19 (4.8) 305 (77.2) 5 (1.26)
 Age at diagnosis, years 36.68 (6.06) 37.51 (4.92) 36.05 (5.96) 41.98 (2.51) 0.722 0.001a 39.2 (6.72) 39.42 (5.71) 38.07 (6.06) 44.4 (1.34) 0.03 0.045 0.0028a <0.0001a
 Duration of diabetes, years 10.38 (7.37) 5.79 (7.53) 9.34 (8.00) 8.57 (7.53) 0.070 --
 BMI, kg/m2 26.07 (3.82) 28.23 (5.92) 28.18 (4.22) 21.69 (2.75) <0.0001a <0.0001a 30.65 (7.92) 36.51 (6.67) 34.33 (6.90) 21.54 (1.19) <0.0001a <0.0001a <0.0001a <0.0001a
 Fasting glucose, mmol/l 11.64 (3.53) 5.89 (1.44) 7.98 (2.33) 6.33 (0.97) <0.0001a <0.0001a 11.61 (4.11) 6.63 (1.08) 7.76 (1.88) 6.66 (1.62) <0.0001a <0.0001a 0.92 0.19
 HbA1c, mmol/mol 91.22 (16.11) 59.63 (13.21) 57.34 (12.57) 44.85 (12.98) <0.0001a <0.0001a 103.48 (17.35) 53.39 (13.88) 52.41 (14.12) 48.15 (9.04) <0.0001a <0.0001a <0.0001a <0.0001a
 HbA1c, % 10.5 (3.6) 7.6 (3.4) 7.4 (3.3) 6.3 (3.3) <0.0001a <0.0001a 11.7 (3.7) 7.0 (3.4) 6.9 (3.4) 6.6 (3.0) <0.0001a <0.0001a <0.0001a <0.0001a
 Fasting C-peptide, nmol/l 0.71 (0.41) 1.98 (0.63) 0.77 (0.42) 0.42 (0.20) 0.479 <0.0001a 0.90 (0.5) 2.43 (0.61) 1.19 (0.46) 0.76 (0.23) <0.0001a <0.0001a 0.0013a <0.0001a
 HOMA2-B 34.67 (21.47) 209.54 (41.32) 68.5 (39.13) 59.05 (19.27) <0.0001a <0.0001a 46.29 (35.19) 193.47 (37.16) 90.94 (35.22) 86.78 (30.71) <0.0001a <0.0001a 0.00052a <0.0001a
 HOMA2-IR 2.29 (1.49) 4.63 (1.71) 1.98 (1.12) 1.03 (0.47) <0.0001a <0.0001a 2.9 (1.78) 5.74 (1.39) 3.03 (1.30) 1.84 (0.61) <0.0001a <0.0001a 0.0043a <0.0001a

Note: Values are mean (SD) unless otherwise indicated

aBonferroni corrected significant p values

p value by ANOVA, p1 adjusted for duration of diabetes